Akebia Therapeutics (AKBA) Cash & Equivalents (2013 - 2026)
Akebia Therapeutics (AKBA) reported Cash & Equivalents of $155.55 million for Q2 2026, up 13.3% from $137.31 million a year earlier but down 4.4% from the prior quarter.
Powered by 
Analysis
Akebia Therapeutics (AKBA) Cash & Equivalents (2013 - 2026) Analysis & Trends
At the end of FY2025, Akebia Therapeutics posted Cash & Equivalents of $184.84 million, up 256.4% from FY2024.
- Cash & Equivalents has a five-year compound annual growth rate of -4.2% (FY2020 to FY2025).
- By year, Cash & Equivalents came in at $51.87 million in FY2024 (+20.8%), $42.93 million in FY2023 (-52.6%), $90.47 million in FY2022 (-39.6%) and $149.8 million in FY2021 (-34.5%).
- Five-year quarterly Cash & Equivalents spans a low of $34.02 million in Q3 2024 and a high of $207.2 million in Q3 2021.
- Year over year, Cash & Equivalents has now increased in each of the last seven quarters, with growth averaging 139.2% over the last eight quarters.
- The high point for year-over-year Cash & Equivalents in five years was Q3 2025 (growth of 389.3%); the low point was Q3 2023 (a decline of 67.9%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $162.64 million (Q1 2026), $184.84 million (Q4 2025) and $166.44 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Akebia Therapeutics | 236.42 Mn | -433.06 Mn | 38.70 Mn | 155.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 155.55 Mn |
| Mar 31, 2026 | 162.64 Mn |
| Dec 31, 2025 | 184.84 Mn |
| Sep 30, 2025 | 166.44 Mn |
| Jun 30, 2025 | 137.31 Mn |
| Mar 31, 2025 | 113.40 Mn |
| Dec 31, 2024 | 51.87 Mn |
| Sep 30, 2024 | 34.02 Mn |
| Jun 30, 2024 | 39.50 Mn |
| Mar 31, 2024 | 42.00 Mn |
| Dec 31, 2023 | 42.93 Mn |
| Sep 30, 2023 | 46.53 Mn |
| Jun 30, 2023 | 53.60 Mn |
| Mar 31, 2023 | 57.00 Mn |
| Dec 31, 2022 | 90.47 Mn |
| Sep 30, 2022 | 144.80 Mn |
| Jun 30, 2022 | 143.90 Mn |
| Mar 31, 2022 | 174.60 Mn |
| Dec 31, 2021 | 149.80 Mn |
| Sep 30, 2021 | 207.20 Mn |
API Access
Akebia Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=AKBA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "AKBA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=AKBA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();